Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.53 |
| ▸ | CHUK | O15111 | 6/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686986 | 0.93 | IKBKB (0.60) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL552458 | 0.84 | IKBKB (0.70) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL10050273 | 0.81 | IKBKB (0.60) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL551959 | 0.80 | IKBKB (0.68) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL3803112 | 0.79 | IKBKB (0.82) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL553113 | 0.79 | IKBKB (0.68) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL553393 | 0.78 | IKBKB (0.69) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL553388 | 0.75 | IKBKB (0.73) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL552321 | 0.75 | IKBKB (0.72) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL3796669 | 0.74 | IKBKB (0.67) | IKBKBCHUKBTKAURKAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| CN-106103423-B | Pyrazine compounds | 阿斯利康(瑞典)有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| EP-3119752-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140527-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | IKBKB 1053/4885CHUK 1034/4885BTK 2318/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | IKBKB 1053/4885CHUK 1034/4885BTK 2318/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | IKBKB 1053/4885CHUK 1034/4885BTK 2318/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | IKBKB 1053/4885CHUK 1034/4885BTK 2318/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | IKBKB 1053/4885CHUK 1034/4885BTK 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.